NY GU: 9th Annual Interdisciplinary Prostate Cancer Congress and other GU Malignancies
New York GU: 9th Annual Interdisciplinary Prostate Cancer Congress® and other Genitourinary Malignancies
Saturday, March 19, 2016
Crowne Plaza® Times Square Manhattan
1605 Broadway (at 49th Street)
New York, NY 10019
The New York GU™: 9th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
is an intensive, interactive, one-day educational program that brings together renowned national experts in the fields of genitourinary malignancies treatment.
will focus on key clinical topics in the management of genitourinary malignancies, including prognostic/predictive markers in care, proactive methods to mitigate predictable treatment-related side effects, optimal use of chemotherapeutic strategies, androgen deprivation therapies, targeted therapies, radiopharmaceuticals, and immunotherapies, as well as exploring emerging data on various combinations and sequences of treatment strategies currently undergoing clinical trial evaluation. This year, there will be a particular and expanded focus on bladder cancer and renal cell carcinoma, given recent practice-changing developments that are altering the therapeutic landscape in these fields of care. Key questions concerning the application of landmark clinical trial data on emerging targeted and immunotherapeutic options, as well as the application of evolving biomarkers for these tumors, will be answered during expanded sessions on these topics this year.
This year's New York GU™
meeting is not to be missed! The program is sure to continue its legacy and tradition to provide clinicians with the knowledge and confidence to maintain state-of-the-art care, and optimize outcomes for patients with genitourinary malignancies.
This educational activity is directed toward medical oncologists, radiation oncologists, surgeons, and urologists involved in the treatment and management of patients with prostate cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals interested in the treatment of prostate cancer may also participate.
At the conclusion of this activity, participants should be better prepared to:
Describe methods to stratify risk and tumor information that can provide the rationale for clinical decision-making in the management of genitourinary (GU) malignancies
Summarize recommendations that shape current strategies to care for patients with GU malignancies
Develop multidisciplinary strategies to optimize outcomes by proactive mitigation of known treatment-related side effects in caring for patients with GU malignancies
Assess recent practice-changing clinical trial findings concerning novel compounds or strategies to manage GU malignancies
Apply emerging clinical concepts to support the management of GU malignancies in consideration of evolving treatment paradigms in the field
Daniel P. Petrylak, MD
Professor of Medicine, Medical Oncology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Program
Yale Cancer Center
New Haven, CT
Leonard G. Gomella, MD, FACS
The Bernard W. Godwin Professor of Prostate Cancer
Chairman, Department of Urology
Associate Director, Jefferson Kimmel Cancer Center
Clinical Director Jefferson Kimmel Cancer Center Network
Thomas Jefferson University